Company: Rebiotix, a Ferring Company
Job title: VP Microbiome Research & CSO
Ken Blount, PhD, is a seasoned director of collaborative research programs in biotech, pharma, clinical, and academic research settings, and his scientific expertise includes antibiotics discovery and development, fecal microbiome analysis, translational medical oncology, and RNA-targeting therapeutics. Prior to joining Rebiotix, a Ferring Company, Dr. Blount coordinated translational urologic oncology research for the Yale Cancer Center. Previously, he was a cofounder and the Director of Biology at BioRelix, a venture-backed Connecticut biotech that developed new antibiotics to target structured bacterial messenger RNAs. At BioRelix, Dr. Blount led a combined force of internal scientists and external resources that delivered development candidates for treating Clostridium difficile infections.
Dr. Blount received his undergraduate degree in biochemistry from the University of Arkansas and earned a PhD in biochemistry from the University of Colorado Boulder, after which he completed an NIH post-doctoral fellowship at the University of California San Diego.
Industry Leaders Panel Discussion 8:45 am
What are the decisions industry pioneers have made/are making to ensure progress within this novel industry? What are the unique characteristics of microbiome therapeutics and how can they change the paradigm of healthcare? Benchmarking how microbiome therapeutics compare against existing traditional approaches already on the market? What are the biggest challenges currently facing microbiome drug…Read more
day: Day One